Needham analyst Joseph Stringer maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report) today and set a price target of $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Stringer has given his Buy rating due to a combination of factors surrounding Cidara Therapeutics. The company is poised to provide more detailed insights into their Phase 2b Flu trial during an upcoming R&D day, which is expected to shed light on the statistical analysis plan and the commercial potential of their CD388 product. This upcoming event is likely to offer investors a clearer understanding of the company’s strategic direction and competitive positioning.
Additionally, recent discussions with the FDA regarding potential changes to the trial’s statistical analysis plan suggest a proactive approach by Cidara to align with regulatory expectations. These developments, coupled with the anticipation of topline results from the trial in late June, create a promising outlook for the company’s future performance, justifying the Buy rating.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $47.00 price target.